论文部分内容阅读
对国内研制的左旋18甲基炔诺酮皮下埋植剂Ⅱ型(Sino-implant)进行临床预初试验。接收40岁以下、已婚、已育的健康妇女,对孕酮无禁忌症者共193例,到1995年3月全部完成5年随访。1,2.3,4和5年的累积继用率分别为97.4％、93.3％、88.1％、82.9％和76.7％。使用的头2年无妊娠发生,5年累积妊娠率为2.1/100妇女,主要副反应和终止使用的原因为月经失调。埋植剂使用1～5年血红蛋白稍有增加,平均体重和血压改变不明显。2根埋植剂的放置及取出手术操作较6根方便,深受受术者的欢迎。
The clinical pre-test was carried out on Sino-implant L-18 norepinephrine implants developed in China. A total of 193 under-40 married, well-educated and healthy women with no contraindications to progesterone were enrolled. All patients were followed up for 5 years by March 1995. The cumulative success rates at 1, 2.3, 4 and 5 years were 97.4%, 93.3%, 88.1%, 82.9% and 76.7% respectively. The first 2 years of pregnancy were used without pregnancy, with a 5-year cumulative pregnancy rate of 2.1 / 100 women. The main side effects and discontinuation were menstrual disorders. Implants 1 to 5 years using hemoglobin slightly increased, the average weight and blood pressure did not change significantly. 2 implants placed and removed more than 6 surgical operations, deeply welcomed by the surgeon.